Cetera Advisor Networks LLC Buys 2,253 Shares of Eli Lilly and Co (LLY)
Cetera Advisor Networks LLC increased its stake in Eli Lilly and Co (NYSE:LLY) by 10.3% during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 24,081 shares of the company’s stock after buying an additional 2,253 shares during the period. Cetera Advisor Networks LLC’s holdings in Eli Lilly and were worth $2,061,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors also recently bought and sold shares of LLY. Vanguard Group Inc. lifted its position in Eli Lilly and by 2.3% in the 2nd quarter. Vanguard Group Inc. now owns 70,207,891 shares of the company’s stock valued at $5,778,109,000 after acquiring an additional 1,610,885 shares in the last quarter. BlackRock Inc. lifted its position in Eli Lilly and by 2.1% in the 2nd quarter. BlackRock Inc. now owns 63,583,747 shares of the company’s stock valued at $5,232,942,000 after acquiring an additional 1,323,259 shares in the last quarter. Janus Henderson Group PLC lifted its position in Eli Lilly and by 16.1% in the 3rd quarter. Janus Henderson Group PLC now owns 10,857,193 shares of the company’s stock valued at $928,719,000 after acquiring an additional 1,503,918 shares in the last quarter. Janus Capital Management LLC lifted its position in Eli Lilly and by 2.8% in the 1st quarter. Janus Capital Management LLC now owns 8,723,692 shares of the company’s stock valued at $733,731,000 after acquiring an additional 237,619 shares in the last quarter. Finally, Dodge & Cox lifted its position in Eli Lilly and by 22,094.9% in the 2nd quarter. Dodge & Cox now owns 5,991,952 shares of the company’s stock valued at $493,138,000 after acquiring an additional 5,964,955 shares in the last quarter. Institutional investors own 76.30% of the company’s stock.
In related news, SVP Alfonso G. Zulueta sold 2,003 shares of the firm’s stock in a transaction on Friday, November 10th. The stock was sold at an average price of $83.67, for a total value of $167,591.01. Following the transaction, the senior vice president now directly owns 43,580 shares of the company’s stock, valued at approximately $3,646,338.60. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, major shareholder Lilly Endowment Inc sold 200,000 shares of the firm’s stock in a transaction on Wednesday, December 13th. The stock was sold at an average price of $88.20, for a total value of $17,640,000.00. Following the completion of the transaction, the insider now directly owns 123,084,104 shares in the company, valued at $10,856,017,972.80. The disclosure for this sale can be found here. Insiders have sold a total of 251,088 shares of company stock worth $22,041,236 over the last three months. Insiders own 0.20% of the company’s stock.
Several research firms recently issued reports on LLY. Morgan Stanley set a $86.00 price objective on Eli Lilly and and gave the company a “hold” rating in a research report on Friday, October 6th. Leerink Swann upped their price objective on Eli Lilly and from $92.00 to $93.00 and gave the company a “market perform” rating in a research report on Monday, October 23rd. BMO Capital Markets set a $73.00 price objective on Eli Lilly and and gave the company a “sell” rating in a research report on Tuesday, October 24th. Credit Suisse Group cut Eli Lilly and from an “outperform” rating to a “neutral” rating and upped their price objective for the company from $84.23 to $88.00 in a research report on Tuesday, October 10th. Finally, Goldman Sachs Group reaffirmed a “buy” rating and issued a $95.00 price objective (up from $92.00) on shares of Eli Lilly and in a research report on Thursday, October 5th. Three investment analysts have rated the stock with a sell rating, six have assigned a hold rating and ten have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $92.14.
Eli Lilly and Co (LLY) opened at $86.57 on Friday. The firm has a market capitalization of $95,320.00, a price-to-earnings ratio of 41.22, a PEG ratio of 1.60 and a beta of 0.35. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.03 and a current ratio of 1.38. Eli Lilly and Co has a twelve month low of $74.00 and a twelve month high of $89.09.
Eli Lilly and (NYSE:LLY) last released its quarterly earnings results on Tuesday, October 24th. The company reported $1.05 earnings per share for the quarter, beating the consensus estimate of $1.03 by $0.02. The firm had revenue of $5.66 billion for the quarter, compared to analysts’ expectations of $5.52 billion. Eli Lilly and had a return on equity of 30.27% and a net margin of 9.90%. The company’s revenue was up 9.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.88 EPS. sell-side analysts predict that Eli Lilly and Co will post 4.22 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Friday, March 9th. Stockholders of record on Thursday, February 15th will be issued a dividend of $0.5625 per share. This represents a $2.25 annualized dividend and a dividend yield of 2.60%. This is a boost from Eli Lilly and’s previous quarterly dividend of $0.52. The ex-dividend date of this dividend is Wednesday, February 14th. Eli Lilly and’s dividend payout ratio is presently 99.05%.
COPYRIGHT VIOLATION WARNING: This piece was first published by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another site, it was copied illegally and reposted in violation of international copyright law. The correct version of this piece can be viewed at https://www.watchlistnews.com/cetera-advisor-networks-llc-buys-2253-shares-of-eli-lilly-and-co-lly/1796807.html.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Co (NYSE:LLY).
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with Analyst Ratings Network's FREE daily email newsletter.